EPS for Swedish Orphan Biovitrum AB (publ) Expected At $0.21 on July, 18

June 27, 2018 - By Edith Ladford

Swedish Orphan Biovitrum AB (OTCMKTS:publ) Corporate Logo

On July, 18 WallStreet anticipated Swedish Orphan Biovitrum AB (OTCMKTS:publ)’s earnings report, RTT reports. If $0.21 is reported, SWTUY’s profit will reach $57.46M for 25.65 P/E. After $0.24 EPS report last quarter, Wall Street now sees -12.50 % negative EPS growth of Swedish Orphan Biovitrum AB. The stock decreased 2.36% or $0.52 during the last trading session, hitting $21.55.Swedish Orphan Biovitrum AB is after having 0.00% since June 27, 2017. publ has 965 volume or 315.95% up from normal. publ underperformed the S&P500 by 12.57%.

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, makes, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally.The company has $5.90 billion market cap. The Company’s core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.35.5 is the P/E ratio. The firm also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: